Mechanisms for anti-inflammatory effects of 1-[15(S)- hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan A-induced peritonitis

British Journal of Pharmacology

Volumn 162, Issue 5, 2011, Pages 1119-1135

  Hung, Nguyen Dang ^a   Kim, Mee Ree ^a   Sok, Dai Eun ^a  

^a Chungnam National University   (South Korea)

Author keywords

1 15(S) hydroxypentaenoyl lysoPC; anti inflammatory; IL 6; LTB 4; LTC 4; PGE 2; TNF ; zymosan A

Indexed keywords

1 (15 HYDROPEROXYPENTAENOYL)LYSOPHOSPHATIDYLCHOLINE; 1 (15 HYDROXYEICOSAPENTAENOYL)LYSOPHOSPHATIDYLCHOLINE; 1 EICOSAPENTAENOYL LYSOPHOSPHATIDYLCHOLINE; ARACHIDONATE 15 LIPOXYGENASE; GAMMA INTERFERON; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LEUKOTRIENE B4; LEUKOTRIENE C4; LIPOXIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME ACTIVITY; MALE; MICHAELIS MENTEN KINETICS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXYGENATION; PERITONEUM CELL; PERITONITIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; EICOSAPENTAENOIC ACID; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; LEUKOCYTES; LEUKOTRIENE B4; LEUKOTRIENE C4; LYSOPHOSPHATIDYLCHOLINES; MALE; MICE; MICE, INBRED ICR; OLIGOPEPTIDES; OXIDATION-REDUCTION; PERITONITIS; STRUCTURE-ACTIVITY RELATIONSHIP; ZYMOSAN;

EID: 79551490190     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01117.x     Document Type: Article

References (80)

1. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. (2005a). Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201: 713-722.
2. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, et al. (2005b). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102: 7671-7676.
3. Bannenberg G, Moussignac RL, Gronert K, Devchand PR, Schmidt BA, Guilford WJ, et al. (2004). Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 143: 43-52.
4. Bazan NG, (2009). Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 50: 400-405.
5. Bertolini A, Ottani A, Sandrini M, (2001). Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res 44: 437-450.
6. Bradley PP, Priebat DA, Christensen RD, Rothstein G, (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206-209.
7. Burkert E, Szellas D, Radmark O, Steinhilber D, Werz O, (2003). Cell type-dependent activation of 5-lipoxygenase by arachidonic acid. J Leukoc Biol 73: 191-200.
8. Byrum RS, Goulet JL, Snouwaert JN, Griffiths RJ, Koller BH, (1999). Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 163: 6810-6819.
9. Chakrabarti SK, Cole BK, Wen YS, Keller SR, Nadler JL, (2009). 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity 17: 1657-1663.
10. Chiang N, Arita M, Serhan CN, (2005). Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 73: 163-177.
11. Colles SM, Chisolm GM, (2000). Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J Lipid Res 41: 1188-1198.
12. Dimitrova P, Ivanovska N, (2008). Tyrphostin AG-490 inhibited the acute phase of zymosan-induced inflammation. Int Immunopharmacol 8: 1567-1577.
13. Doherty NS, Poubelle P, Borgeat P, Beaver TH, Westrich GL, Schrader NL, (1985). Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E2. Prostaglandins 30: 769-789.
14. Engelmann B, Zieseniss S, Brand K, Page S, Lentschat A, Ulmer AJ, et al. (1999). Tissue factor expression of human monocytes is suppressed by lysophosphatidylcholine. Arterioscler Thromb Vasc Biol 19: 47-53.
15. Fox LM, Cox DG, Lockridge JL, Wang XH, Chen XX, Scharf L, et al. (2009). Recognition of Lyso-Phospholipids by Human Natural Killer T Lymphocytes. PLoS Biol 7: e1000228. DOI: 10.1371/journal.pbio.1000228.
16. Fuentes L, Hernandez M, Fernandez-Aviles FJ, Crespo MS, Nieto ML, (2002). Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis. Circ Res 91: 681-688.
17. Funk CD, (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875.
18. Gonzalez-Periz A, Planaguma A, Gronert K, Miquel R, Lopez-Parra M, Titos E, et al. (2006). Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J 20: 2537-2539.
19. Griswold DE, Webb EF, Hillegass LM, (1991). Induction of plasma exudation and inflammatory cell infiltration by leukotriene C4 and leukotriene B4 in mouse peritonitis. Inflammation 15: 251-258.
20. Guzik TJ, Korbut R, Adamek-Guzik T, (2003). Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54: 469-487.
21. Haberland ME, Reynolds JA, (1975). Interaction of L-alpha-palmitoyl lysophosphatidylcholine with the AI polypeptide of high density lipoprotein. J Biol Chem 250: 6636-6639.
22. Ho HY, Wong PYK, (1990). Transformation of 15-hydroperoxide of eicosapentaenoic acid to lipoxins and trihydroxyeicosatetraenoic acids by 5-lipoxygenase partially purified from potato-tubers. Eicosanoids 3: 99-104.
23. Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN, (2008). Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol 180: 3512-3519.
24. Huang LS, Kim MR, Sok DE, (2006). Linoleoyl lysophosphatidylcholine is an efficient substrate for soybean lipoxygenase-1. Arch Biochem Biophys 455: 119-126.
25. Huang LS, Kim MR, Sok DE, (2007). Oxygenation of 1-docosahexaenoyl lysophosphatidylcholine by lipoxygenases; conjugated hydroperoxydiene and dihydroxytriene derivatives. Lipids 42: 981-990.
26. Huang LS, Kang JS, Kim MR, Sok DE, (2008a). Oxygenation of arachidonoyl lysophospholipids by lipoxygenases from soybean, porcine leukocyte, or rabbit reticulocyte. J Agric Food Chem 56: 1224-1232.
27. Huang LS, Kim MR, Sok DE, (2008b). Regulation of lipoxygenase activity by polyunsaturated lysophosphatidylcholines or their oxygenation derivatives. J Agric Food Chem 56: 7808-7814.
28. Huang LS, Kim MR, Sok DE, (2009). Enzymatic reduction of polyunsaturated lysophosphatidylcholine hydroperoxides by glutathione peroxidase-1. Eur J Lipid Sci Technol 111: 584-592.
29. Huang LS, Hung ND, Sok DE, Kim MR, (2010). Lysophosphatidylcholine containing docosahexaenoic acid at the sn-1 position is anti-inflammatory. Lipids 45: 225-236.
30. Hung ND, Kim MR, Sok DE, (2009). Anti-inflammatory action of arachidonoyl lysophosphatidylcholine or 15-hydroperoxy derivative in zymosan A-induced peritonitis. Prostaglandins Other Lipid Mediat 90: 105-111.
31. Hung ND, Kim MR, Sok DE, (2010). Oral administration of 2-docosahexaenoyl lysophosphatidylcholine displayed anti-inflammatory effects on zymosan A-induced peritonitis. Inflammation DOI: 10.1007/s10753-010-9218-z.
32. Jackson SK, Abate W, Tonks AJ, (2008). Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery. Pharmacol Ther 119: 104-114.
33. Jeon SG, Moon HG, Kim YS, Choi JP, Shin TS, Hong SW, et al. (2009). 15-lipoxygenase metabolites play an important role in the development of a T-helper type 1 allergic inflammation induced by double-stranded RNA. Clin Exp Allergy 39: 908-917.
34. Kolaczkowska E, Barteczko M, Plytycz B, Arnold B, (2008). Role of lymphocytes in the course of murine zymosan-induced peritonitis. Inflamm Res 57: 272-278.
35. Lam BK, Wong PY, (1988). Biosynthesis and biological activities of lipoxin A5 and B5 from eicosapentaenoic acid. Adv Exp Med Biol 229: 51-59.
36. Lam BK, Hirai A, Yoshida S, Tamura Y, Wong PY, (1987). Transformation of 15-hydroperoxyeicosapentaenoic acid to lipoxin A5 and B5, mono- and dihydroxyeicosapentaenoic acids by porcine leukocytes. Biochim Biophys Acta 917: 398-405.
37. Leite DFP, Echevarria-Lima J, Ferreira SC, Calixto JB, Rumjanek VM, (2007). ABCC transporter inhibition reduces zymosan-induced peritonitis. J Leukoc Biol 82: 630-637.
38. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN, (2001). Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2: 612-619.
39. Maderna P, Godson C, (2009). Lipoxins: resolutionary road. Br J Pharmacol 158: 947-959.
40. Maskrey BH, O'Donnell VB, (2008). Analysis of eicosanoids and related lipid mediators using mass spectrometry. Biochem Soc Trans 36: 1055-1059.
41. Matsubara M, Hasegawa K, (2005). Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis 178: 57-66.
42. Miller CC, Ziboh VA, (1988). Human-epidermis transforms eicosapentaenoic acid to 15-hydroxy 5,8,11,13,17-eicosapentaenoic acid-a potent inhibitor of 5-lipoxygenase. J Am Oil Chem Soc 65: 474-474.
43. Miller C, Yamaguchi RY, Ziboh VA, (1989). Guinea pig epidermis generates putative anti-inflammatory metabolites from fish oil polyunsaturated fatty acids. Lipids 24: 998-1003.
44. Moreno JJ, (2009a). Differential effects of arachidonic and eicosapentaenoic acid-derived eicosanoids on polymorphonuclear transmigration across endothelial cell cultures. J Pharmacol Exp Ther 331: 1111-1117.
45. Moreno JJ, (2009b). New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochem Pharmacol 77: 1-10.
46. Morgan AH, Dioszeghy V, Maskrey BH, Thomas CP, Clark SR, Mathie SA, et al. (2009). Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. J Biol Chem 284: 21185-21191.
47. Muralikrishna Adibhatla R, Hatcher JF, (2006). Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40: 376-387.
48. NRC (National Research Council) (1996). Guide for the Care and Use of Laboratory Animals of Institute of Laboratory Animal Resources Commission on Life Sciences. National Academy Press: Washington, DC.
49. Park CH, Kim MR, Han JM, Jeong TS, Sok DE, (2009). Lysophosphatidylcholine exhibits selective cytotoxicity, accompanied by ROS formation, in RAW 264.7 macrophages. Lipids 44: 425-435.
50. Perez-Chacon G, Astudillo AM, Balgoma D, Balboa MA, Balsinde J, (2009). Control of free arachidonic acid levels by phospholipases A(2) and lysophospholipid acyltransferases. Biochim Biophys Acta Mol Cell Biol Lipids 1791: 1103-1113.
51. Pettitt TR, Rowley AF, Barrow SE, Mallet AI, Secombes CJ, (1991). Synthesis of lipoxins and other lipoxygenase products by macrophages from the rainbow-trout, oncorhynchus-mykiss. J Biol Chem 266: 8720-8726.
52. Pouliot M, Clish CB, Petasis NA, Van Dyke TE, Serhan CN, (2000). Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39: 4761-4768.
53. Radmark O, Samuelsson B, (2010). Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem Biophys Res Commun 396: 105-110.
54. Rao NL, Dunford PJ, Xue X, Jiang X, Lundeen KA, Coles F, et al. (2007). Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 321: 1154-1160.
55. Rao TS, Currie JL, Shaffer AF, Isakson PC, (1994). In-vivo characterization of zymosan-induced mouse peritoneal inflammation. J Pharmacol Exp Ther 269: 917-925.
56. Rowley AF, Lloydevans P, Barrow SE, Serhan CN, (1994). Lipoxin biosynthesis by trout macrophages involves the formation of epoxide intermediates. Biochemistry 33: 856-863.
57. Schwab JM, Serhan CN, (2006). Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 6: 414-420.
58. Schwab JM, Chiang N, Arita M, Serhan CN, (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
59. Serhan CN, (2005a). Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73: 141-162.
60. Serhan CN, (2005b). Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 8: 115-121.
61. Serhan CN, Savill J, (2005). Resolution of inflammation: the beginning programs the end. Nat Immunol 6: 1191-1197.
62. Serhan CN, Chiang N, Van Dyke TE, (2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361.
63. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et al. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206: 15-23.
64. Shi Y, Zhang P, Zhang L, Osman H, Mohler ER, 3rd, Macphee C, et al. (2007). Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 191: 54-62.
65. Sok DE, Kang JB, Shin HD, (1988). 15-Hydroxyeicosatetraenoic acid dehydrogenase-activity in microsomal fraction of mouse-liver homogenate. Biochem Biophys Res Commun 156: 524-529.
66. Spite M, Summers L, Porter TF, Srivastava S, Bhatnagar A, Serhan CN, (2009). Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Br J Pharmacol 158: 1062-1073.
67. Stahl GL, Tsao P, Lefer AM, Ramphal JY, Nicolaou KC, (1989). Pharmacologic profile of lipoxins A5 and B5: new biologically active eicosanoids. Eur J Pharmacol 163: 55-60.
68. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, et al. (2007). Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 282: 9323-9334.
69. Takeshita S, Inoue N, Gao D, Rikitake Y, Kawashima S, Tawa R, et al. (2000). Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase. J Atheroscler Thromb 7: 238-246.
70. Ternowitz T, Fogh K, Kragballe K, (1988). 15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits LTB4-induced chemotaxis of human neutrophils. Skin Pharmacol 1: 93-99.
71. Thomas CP, Morgan LT, Maskrey BH, Murphy RC, Kuhn H, Hazen SL, et al. (2010). Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation. J Biol Chem 285: 6891-6903.
72. Thumser AEA, Voysey JE, Wilton DC, (1994). The binding of lysophospholipids to rat-liver fatty-acid-binding protein and albumin. Biochem J 301: 801-806.
73. Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, Hong S, et al. (2006). Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol 13: 1193-1202.
74. Tsunomori M, Fujimoto Y, Muta E, Nishida H, Sakuma S, Fujita T, (1996). 15-hydroperoxyeicosapentaenoic acid inhibits arachidonic acid metabolism in rabbit platelets more potently than eicosapentaenoic acid. Biochim Biophys Acta Lipids Lipid Metabol 1300: 171-176.
75. Vang K, Ziboh VA, (2005). 15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids. Prostaglandins Leukot Essent Fatty Acids 72: 363-372.
76. Wall R, Ross RP, Fitzgerald GF, Stanton C, (2010). Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 68: 280-289.
77. von der Weid PY, Hollenberg MD, Fiorucci S, Wallace JL, (2004). Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 110: 1320-1325.
78. Wen Y, Gu J, Chakrabarti SK, Aylor K, Marshall J, Takahashi Y, et al. (2007). The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages. Endocrinology 148: 1313-1322.
79. Wong PY, Hughes R, Lam B, (1985). Lipoxene: a new group of trihydroxy pentaenes of eicosapentaenoic acid derived from porcine leukocytes. Biochem Biophys Res Commun 126: 763-772. (Pubitemid 15130446)
80. Yuhki KI, Ushikubi F, Naraba H, Ueno A, Kato H, Kojima F, et al. (2008). Prostaglandin I-2 plays a key role in zymosan-induced mouse pleurisy. J Pharmacol Exp Ther 325: 601-609.